Bluechip Pharma Stocks At 52-Week Lows; Should You Buy?

Posted By:
Subscribe to GoodReturns
For Quick Alerts
For Daily Alerts

    The miseries for pharma stocks just does not seem to end. We now have several stocks hitting 52-week lows with Lupin Ltd and Aurobindo Pharma, joining the likes of Dr Reddy's at 52-week lows. Other stocks like Sun Pharma and Divis are not very far from their 52-week lows. So, what do we do with pharma stocks?


    If you want to go by valuations, pharma stocks are still not very cheap. Stocks like Dr Reddys, Divis Labs etc., are still pretty much expensive. The only stocks that still looks realistically priced is the stock of Lupin Ltd, which is trading at around 15 times one year forward earnings. We wish to clarify that the earnings could change dramatically on either side, which makes some of these stocks a good as well as a bad bet.

    A lot depends on the US FDA

    We mentioned that results could change dramatically and here are the reasons. Indian pharma companies get a substantial part of their revenues from the United States. Now, the United States, does not allow you to freely export to the US, unless they do a thorough quality check. So, the US FDA comes to India and examines the quality compliance of Indian pharma plants exporting to the US. If the quality of the drugs exported to the US, is not as per their stringent quality requirements a warning is issued and if rectification does not take place, an import alert is issued. This means a particular company cannot export to the US from that plant or facility.

    Many top companies have faced import alerts

    Many top pharma companies have either been issued warnings or import alerts in the past on select plants. Among these include names like Wockhardt, Sun Pharma, Divis Labs, Lupin, IPCA, Cadilla etc.

    The trend has got worse in the recent past and recently Divis Labs received an import alert for its plant in South India. Of course, one can take remedial action and the import alert gets lifted and this has happened many times in the past. However, the process is long and does take time, so as to ensure that the import alert is lifted.

    Stocks that you can still buy

    Lupin is one stock that could still be a good bet at the current levels. The company recently received an approval from the US FDA to market Olmesartan medomoxil tablets in the US. This is for the treatment of hypertension and this opens up a new avenue for the company. The company has made good progress on complex generics and biosimilars. It has several ANDAs with the US FDA, which could boost revenues in the coming years. A growth in the Japanese markets also leave tremendous potential.

    Valuations of Lupin

    Lupin is among the few stocks that is not very expensive. The stock trades at a p/e of 15 times one year forward earnings. The stock recently has fallen from levels of Rs 1700 to the current levels of Rs 1264. At around the Rs 1200 levels, the stock would be an excellent long-term bet.

    Check stock quote of Lupin here




    This article is strictly for informational purposes only. It is not a solicitation to buy, sell in securities or other financial instruments. Greynium Information Technologies Pvt Ltd, its subsidiaries, associates and the author of this article do not accept culpability for losses and/or damages arising based on information in this article. 

    Read more about: divis labs lupin wockhardt
    Company Search
    Enter the first few characters of the company's name or the NSE symbol or BSE code and click 'Go'

    Find IFSC

    Get Latest News alerts from Goodreturns

    We use cookies to ensure that we give you the best experience on our website. This includes cookies from third party social media websites and ad networks. Such third party cookies may track your use on Goodreturns sites for better rendering. Our partners use cookies to ensure we show you advertising that is relevant to you. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on Goodreturns website. However, you can change your cookie settings at any time. Learn more